quality-adjusted life year
QALY; a metric measuring a year of life gained adjusted downward for the proportion spent with side effects or poor quality, used to set drug prices.
As defined in Vincent Rajkumar on the High Price of Cancer Drugs
Where it comes up · 3
- Vinay Prasad on Cancer Drugs, Medical Ethics, and Malignant2 claims
- Vincent Rajkumar on the High Price of Cancer Drugs1 claim
- Alex Telford - Unlocking Innovation in Pharma - [Invest Like the Best, EP.360]1 claim
Most important claims · 4 of 4Search all claims for “quality-adjusted life year” →
- The US is mostly a free pricing system where companies charge what the market will bear, while other countries have governments negotiate prices using metrics such as quality-adjusted life years, and both systems have flaws with no perfect solution.Alex Telford - Unlocking Innovation in Pharma - [Invest Like the Best, EP.360]
- Value-based systems use the quality-adjusted life year, paying for a year of life with no side effects at full value (e.g. $70,000-$80,000 in Europe, 3x GDP per capita per WHO) but discounting the price when the drug makes the patient miserable for part of that time; this places a value on what the drug is worth, not on the patient's life, a distinction patients commonly misunderstand.Vincent Rajkumar on the High Price of Cancer Drugs
- Although exceptional success stories like Imatinib, Rituximab, and Trastuzumab exist, an empirical and broad look at cancer drugs shows they offer marginal benefits—the median improvement in overall survival across 71 consecutively-approved solid-tumor drugs was 2.1 months—while costing $12-16,000 per month for indefinite, non-curative treatment, producing very poor value.Vinay Prasad on Cancer Drugs, Medical Ethics, and Malignant
- Because cancer drugs offer marginal benefits in ideal settings while costing enormous amounts, cost-per-quality-adjusted-life-year figures reach stratospheric levels—around $900,000 for some colon cancer drugs and effectively infinite for drugs like Aflibercept that cost more than alternatives while delivering nothing more—far above the $60-70k UK ceiling or the $200-250k upper limit some US economists endorse.Vinay Prasad on Cancer Drugs, Medical Ethics, and Malignant